Jeannine Denholm
Showing of 85 results
University Hospitals Seidman Cancer Center Named Catalyst Awards Finalist for Excellence in Quality Performance and Measures
Recognized for innovative work improving data integration and enhancing the accuracy and efficiency of tumor registry processes.
Kathy Coleman Commits Additional $3.5 Million to Fuel the Future of Clinical Trials at University Hospitals Seidman Cancer Center
UH plans to triple clinical trials capacity by 2030.
Case Comprehensive Cancer Center receives $25.5M grant renewal to continue work in cancer treatment, prevention, and therapeutic innovation
The renewal marks 38 years of continuous NCI funding, dating back to the organization’s founding in 1987.
Team of Researchers, including University Hospitals Co–Senior Author, Finds not all Low-Grade Prostate Cancers are Low Risk
The study, published July 31 in the journal JAMA Oncology, found that one in six men with GG1 category cancer turns out to have intermediate- or high-risk cancer when other clinical features are considered in addition to biopsy results.
University Hospitals Seidman Cancer Center becomes first in the United States to implement Akesis Inc. innovative Galaxy RTI device for patient treatment
University Hospitals Seidman Cancer Center becomes first in the United States to implement Akesis Inc. innovative Galaxy RTI device for patient treatment
Rare Pancreatic Cancer Patients Show Strong Response to Immunotherapy
University Hospitals Seidman Cancer Center researcher on team who made the first of its kind discovery published in Oncotarget.
University Hospitals Seidman Cancer Center Receives Funding to Implement Improved Symptom Monitoring for Patients Undergoing Cancer Treatment
University Hospitals Seidman Cancer Center Receives Funding to Implement Improved Symptom Monitoring for Patients Undergoing Cancer Treatment.
UH Seidman Cancer Center Researcher Awarded New Gastrointestinal Cancer Grant from NCCN in Collaboration with Taiho Oncology, Inc.
Dr. Madison Conces was awarded for a Phase II Clinical Trial of Trifluridine/Tipiracil plus Oxaliplatin in Patients with Advanced or Metastatic Biliary Tract Cancer Following First-Line Therapy.